The expert explains 2025-1016 flu, COVID-19, and RSV vaccine updates from AAP, ACOG, AAFP, and IDSA, and what changing schedules mean for pharmacists.
Feature|Articles|August 10, 2026
The Effects of COVID-19 Influencing the Development of Vaccines
Author(s)Ashley Gallagher, MA
A decades-long research effort in mRNA-produced licensed vaccines targets influenza, respiratory syncytial virus, cytomegalovirus, HIV, and cancer.
Advertisement
Advertisement
Messenger RNA (mRNA) vaccine technology, first proposed in the early 1970s and confirmed in the laboratory only in the late 1990s, remained a largely experimental concept for 2 more decades.1
Related to this article
Pennsylvania has become the center of the outbreak as cases exceed 775 alongside conflicting mortality reports.
Mark Garofoli, PharmD, BCGP, CPE, CTTS, explains how to guide patients past crowded combination products, uncertain decongestants, and hidden risks in OTC aisles.
Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.
Cohort studies found no clear cardiovascular benefit from PPV23 vaccination, leaving its role in cardiovascular prevention unresolved.
A high-dose flu vaccine lowered flu- and pneumonia-related hospital stays in patients with chronic lung disease, reinforcing flu and pneumococcal vaccinations.
Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Advertisement
Advertisement